|
1
|
Turner EC, Mulvaney EP, Reid HM and
Kinsella BT: Interaction of the human prostacyclin receptor with
the PDZ adapter protein PDZK1: role in endothelial cell migration
and angiogenesis. Mol Biol Cell. 22:2664–2679. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu W, Saddar S, Seetharam D, et al: The
scavenger receptor class B type I adaptor protein PDZK1 maintains
endothelial monolayer integrity. Circ Res. 102:480–487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Honn KV, Cicone B and Skoff A:
Prostacyclin: a potent antimetastatic agent. Science.
212:1270–1272. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gorelik E, Bere WW and Herberman RB: Role
of NK cells in the antimetastatic effect of anticoagulant drugs.
Int J Cancer. 33:87–94. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Menter DG, Harkins C, Onoda J, et al:
Inhibition of tumor cell induced platelet aggregation by
prostacyclin and carbacyclin: an ultrastructural study. Invasion
Metastasis. 7:109–128. 1987.PubMed/NCBI
|
|
6
|
Niitsu Y, Ishigaki S, Kogawa K, et al:
Effect of combined administration of a prostacyclin analogue and
adriamycin against the artificial metastasis of Meth A cell.
Invasion Metastasis. 8:57–72. 1988.PubMed/NCBI
|
|
7
|
Sava G, Perissin L, Zorzet S, Piccini P
and Giraldi T: Antimetastatic action of the prostacyclin analog
iloprost in the mouse. Clin Exp Metastasis. 7:671–678. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Honn KV: Inhibition of tumor cell
metastasis by modulation of the vascular prostacyclin/thromboxane
A2 system. Clin Exp Metastasis. 1:103–114. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karpatkin S, Ambrogio C and Pearlstein E:
Lack of effect of in vivo prostacyclin on the development of
pulmonary metastases in mice following intravenous injection of
CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic
melanoma cells. Cancer Res. 44:3880–3883. 1984.PubMed/NCBI
|
|
10
|
Mahalingam M, Ugen KE, Kao KJ and Klein
PA: Functional role of platelets in experimental metastasis studied
with cloned murine fibrosarcoma cell variants. Cancer Res.
48:1460–1464. 1988.PubMed/NCBI
|
|
11
|
Lapis K, Timár J, Pápay J, Paku S, Szende
B and Ladányi A: Experimental metastasis inhibition by pretreatment
of the host. Arch Geschwulstforsch. 60:97–102. 1990.PubMed/NCBI
|
|
12
|
Kato S, Kobari M, Matsuno S and Sato T:
Inhibitory effect of anti-platelet prostaglandin on liver
metastasis of hamster pancreatic cancer. Nihon Geka Gakkai Zasshi.
90:745–752. 1989.(In Japanese). PubMed/NCBI
|
|
13
|
Schwalke MA, Tzanakakis GN and Vezeridis
MP: Effects of prostacyclin on hepatic metastases from human
pancreatic cancer in the nude mouse. J Surg Res. 49:164–167. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tzanakakis GN, Agarwal KC and Vezeridis
MP: Inhibition of hepatic metastasis from a human pancreatic
adenocarcinoma (RWP-2) in the nude mouse by prostacyclin,
forskolin, and ketoconazole. Cancer. 65:446–451. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Costantini V, Fuschiotti P, Giampietri A,
et al: Effects of a stable prostacyclin analogue on platelet
activity and on host immunocompetence in mice. Prostaglandins.
39:581–599. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pasqualini R, Arap W and McDonald DM:
Probing the structural and molecular diversity of tumor
vasculature. Trends Mol Med. 8:563–571. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Minami Y, Sasaki T, Kawabe J and Ohsaki Y:
Accessory cells in tumor angiogenesis - tumor-associated pericytes.
Research Directions in Tumor Angiogenesis. Chai J: InTech; Croatia:
pp. 73–89. 2013
|
|
18
|
Morikawa S, Baluk P, Kaidoh T, Haskell A,
Jain RK and McDonald DM: Abnormalities in pericytes on blood
vessels and endothelial sprouts in tumors. Am J Pathol.
160:985–1000. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O’Keeffe MB, Devlin AH, Burns AJ, et al:
Investigation of pericytes, hypoxia, and vascularity in bladder
tumors: association with clinical outcomes. Oncol Res. 17:93–101.
2008.
|
|
20
|
Stefansson IM, Salvesen HB and Akslen LA:
Vascular proliferation is important for clinical progress of
endometrial cancer. Cancer Res. 66:3303–3309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yonenaga Y, Mori A, Onodera H, et al:
Absence of smooth muscle actin-positive pericyte coverage of tumor
vessels correlates with hematogenous metastasis and prognosis of
colorectal cancer patients. Oncology. 69:159–166. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xian X, Håkansson J, Ståhlberg A, et al:
Pericytes limit tumor cell metastasis. J Clin Invest. 116:642–651.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawabe J, Yuhki K, Okada M, et al:
Prostaglandin I2 promotes recruitment of endothelial
progenitor cells and limits vascular remodeling. Arterioscler
Thromb Vasc Biol. 30:464–470. 2010. View Article : Google Scholar
|
|
24
|
Ushiki T and Murakumo M: Scanning electron
microscopic studies of tissue elastin components exposed by a
KOH-collagenase or simple KOH digestion method. Arch Histol Cytol.
54:427–436. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tennis MA, Van Scoyk M, Heasley LE, et al:
Prostacyclin inhibits non-small cell lung cancer growth by a
frizzled 9-dependent pathway that is blocked by secreted
frizzled-related protein 1. Neoplasia. 12:244–253. 2010.PubMed/NCBI
|
|
26
|
Honn KV and Meyer J: Thromboxanes and
prostacyclin: positive and negative modulators of tumor growth.
Biochem Biophys Res Commun. 102:1122–1129. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang DG, Grossi IM, Chen YQ, Diglio CA and
Honn KV: 12(S)-HETE promotes tumor-cell adhesion by increasing
surface expression of alpha V beta 3 integrins on endothelial
cells. Int J Cancer. 54:102–111. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Honn KV, Busse WD and Sloane BF:
Prostacyclin and thromboxanes. Implications for their role in tumor
cell metastasis. Biochem Pharmacol. 32:1–11. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Menter DG, Onoda JM, Moilanen D, Sloane
BF, Taylor JD and Honn KV: Inhibition by prostacyclin of the tumor
cell-induced platelet release reaction and platelet aggregation. J
Natl Cancer Inst. 78:961–969. 1987.PubMed/NCBI
|
|
30
|
Menter DG, Onoda JM, Taylor JD and Honn
KV: Effects of prostacyclin on tumor cell-induced platelet
aggregation. Cancer Res. 44:450–456. 1984.PubMed/NCBI
|
|
31
|
Honn KV, Tang DG, Grossi IM, et al:
Enhanced endothelial cell retraction mediated by 12(S)-HETE: a
proposed mechanism for the role of platelets in tumor cell
metastasis. Exp Cell Res. 210:1–9. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Honn KV, Grossi IM, Diglio CA,
Wojtukiewicz M and Taylor JD: Enhanced tumor cell adhesion to the
subendothelial matrix resulting from 12(S)-HETE-induced endothelial
cell retraction. FASEB J. 3:2285–2293. 1989.PubMed/NCBI
|
|
33
|
Honn KV, Tang DG, Grossi I, et al: Tumor
cell-derived 12(S)-hydroxyeicosatetraenoic acid induces
microvascular endothelial cell retraction. Cancer Res. 54:565–574.
1994.PubMed/NCBI
|
|
34
|
Aburakawa Y, Kawabe J, Okada M, et al:
Prostacyclin stimulated integrin-dependent angiogenic effects of
endothelial progenitor cells and mediated potent circulation
recovery in ischemic hind limb model. Circ J. 77:1053–1062. 2013.
View Article : Google Scholar
|
|
35
|
Cipriani P, Marrelli A, Benedetto PD, et
al: Scleroderma Mesenchymal Stem Cells display a different
phenotype from healthy controls; implications for regenerative
medicine. Angiogenesis. 16:595–607. 2013. View Article : Google Scholar : PubMed/NCBI
|
